Group 1 - The core viewpoint of the article highlights that Sangfor Pharmaceuticals (01530) experienced a nearly 5% drop in stock price, trading at HKD 27.76 with a transaction volume of HKD 704 million [1] - Sangfor Pharmaceuticals announced a plan to place 105 million shares at a price of HKD 29.62 per share, aiming to raise a net amount of approximately HKD 30.87 billion [1] - The placement shares represent about 4.14% of the issued share capital post-placement, with the placement price reflecting a discount of 6.50% compared to the previous day's closing price [1] Group 2 - 80% of the funds raised from the placement will be allocated for research and development expenses, while the remaining 20% will be used for working capital [1] - In November, Sangfor Pharmaceuticals announced the spin-off of its hair loss treatment company, Mandi International, for listing [1] - According to research from CMB International, the spin-off is expected to provide short-term investment returns for Sangfor Pharmaceuticals and, in the long term, help the company focus on its core prescription and innovative drug businesses, with the funds supporting the commercialization of self-developed innovative products [1]
港股异动 | 三生制药(01530)现跌近5% 公司近期配股净筹超30亿港元 拟分拆蔓迪国际上市